Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Convertible Debt (2016 - 2025)

Integra Lifesciences Holdings' Convertible Debt history spans 16 years, with the latest figure at $83.5 million for Q3 2025.

  • For Q3 2025, Convertible Debt changed N/A year-over-year to $83.5 million; the TTM value through Sep 2025 reached $83.5 million, changed N/A, while the annual FY2024 figure was $108.1 million, 21.19% up from the prior year.
  • Convertible Debt for Q3 2025 was $83.5 million at Integra Lifesciences Holdings, down from $108.8 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $571.0 million in Q1 2024 and bottomed at $77.7 million in Q2 2024.
  • The 5-year median for Convertible Debt is $112.0 million (2022), against an average of $266.4 million.
  • The largest annual shift saw Convertible Debt skyrocketed 4600.0% in 2021 before it crashed 84.28% in 2023.
  • A 5-year view of Convertible Debt shows it stood at $112.5 million in 2021, then skyrocketed by 404.3% to $567.3 million in 2022, then plummeted by 84.28% to $89.2 million in 2023, then increased by 21.19% to $108.1 million in 2024, then decreased by 22.76% to $83.5 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Convertible Debt are $83.5 million (Q3 2025), $108.8 million (Q2 2025), and $102.1 million (Q1 2025).